+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide



Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide



Thyroid 7(1): 21-29



Thyroid associated ophthalmopathy (TAO) is a disorder involving the soft tissues and extraocular muscles of the orbit seen mainly in cases of Graves' disease. Although an immunogenic pathogenesis has been proposed, the actual mechanisms of the in vivo retrobulbar involvement are not well defined. The recent introduction of the 111In-labeled somatostatin analog, octreotide, which can bind in vivo to the cell membrane of activated lymphocytes expressing somatostatin receptors, has provided a new investigational tool for diseases with a presumed immunological background. Based on this property, octreotide scans can be expected to be positive in cases of immunological disease showing tracer accumulation within affected sites. The aim of this study was to evaluate the utility of scintigraphic imaging with octreotide of the retrobulbar space in cases of TAO, including sequential studies of patients undergoing immunosuppressive therapy. We studied a series of 51 patients who had Graves' disease with varying degrees of TAO. Nine patients had received immunosuppressive therapy. The degree of orbital inflammation was classified according to the clinical activity score of Mourits. Both planar and tomographic imaging of the orbit were carried out using 111 MBq of the 111In-labeled octreotide (OctreoScan) 2 h after tracer injection. A significant tracer accumulation in the retrobulbar space was seen in all 20 patients with a high activity score, in 8 of 16 cases with a negative score, and in 11 of 20 cases with an intermediate Mourits' score. In cases of persistent eye disease in spite of immunosuppressive therapy, the octreotide scan remained positive. Successful therapy either with prednisolone, external radiation, or i.v. immunoglobulins showed a significant diminution of tracer uptake after finishing the therapeutic regime. Three-dimensional reconstruction of the images also revealed a significant tracer accumulation in the areas of the lacrimal gland, the nasal region, and the pituitary. Controls cases (n = 30) showed no uptake in the orbital region. We conclude that 111In octreotide scintigraphy is an objective method that identifies patients with active inflammatory eye disease, i.e., having significant tracer uptake in the retrobulbar space. This uptake appears to reflect an immunological process, since immunosuppressive therapy will significantly decrease tracer accumulation.

(PDF emailed within 0-6 h: $19.90)

Accession: 046010506

Download citation: RISBibTeXText

PMID: 9086565

DOI: 10.1089/thy.1997.7.21


Related references

[111In]-DTPA-D-phenylalanine octreotide SPECT for the scintigraphic imaging of enhanced somatostatin-receptor density in endocrine ophthalmopathy. Rofo 160(1): 11-15, 1994

99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. Journal of Nuclear Medicine 41(6): 1114-1119, 2000

Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study. Kaku Igaku. Japanese Journal of Nuclear Medicine 32(5): 511-521, 1995

Hybrid imaging using 111In Octreotide SPECT/CT in evaluation of somatostatin receptor positive tumors. Journal of Nuclear Medicine 44(5 Supplement): 73P-74P, 2003

The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. Journal of Cancer Research and Clinical Oncology 130(11): 649-656, 2004

111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors. Quarterly Journal of Nuclear Medicine 39(4 Suppl 1): 134-136, 1995

111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy. Nuclear Medicine Communications 16(11): 912-916, 1995

Scintigraphic localization of neuroendocrine tumors and their metastases using a somatostatin analog [111In-DTPA-d-phe1] octreotide. Revue Medicale de Liege 48(6): 326-334, 1993

Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine 46(9): 1561-1569, 2005

Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy. Nuklearmedizin. Nuclear Medicine 34(3): 100-103, 1995

Somatostatin receptor imaging in CNS tumours using 111In-octreotide. Nuclear Medicine Communications 16(9): 756-766, 1995

111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. Journal of Nuclear Medicine 41(4): 636-642, 2000

Somatostatin receptor imaging in small cell lung cancer using 111In-DTPA-octreotide. Nuclear Medicine Communications 14(11): 962-968???968, 1993

Somatostatin receptor imaging in small cell lung cancer using 111In-DTPA-octreotide: a preliminary study. Nuclear Medicine Communications 14(11): 962-968, 1993

Somatostatin receptor imaging in endocrine ophthalmopathy with indium-111 DTPA-PHE-octreotide and high resolution SPECT. Journal of Nuclear Medicine 34(5 SUPPL ): 164P, 1993